Dataset of transcriptomic changes induced by naringenin treatment in MCF-7 breast cancer cellsGene Expression Omnibus
Van T. Hoang,
Mackenzie L. Hawes,
Jack R. Elliott,
Steven Elliott,
Binghao Zou,
Stephen M. Boué,
Brian G. Rowan,
Bridgette M. Collins-Burow,
Jorge A. Belgodere,
Muralidharan Anbalagan,
Elizabeth C. Martin,
Matthew E. Burow
Affiliations
Van T. Hoang
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA; Corresponding authors.
Mackenzie L. Hawes
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA
Jack R. Elliott
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA
Steven Elliott
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA
Binghao Zou
Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA
Stephen M. Boué
U. S. Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, New Orleans, LA 70179, USA
Brian G. Rowan
Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA
Bridgette M. Collins-Burow
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA
Jorge A. Belgodere
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA; Department of Biological and Agricultural Engineering, Louisiana State University and Agricultural Center, Baton Rouge, LA 70803, USA
Muralidharan Anbalagan
Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA
Elizabeth C. Martin
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA
Matthew E. Burow
Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University, New Orleans, LA 70112, USA; Corresponding authors.
Naringenin (Nar) is a citrus fruit-derived phytoestrogen, a group of dietary compounds produced by a wide variety of plants. Due to structural similarity to 17‐β‐estradiol (E2), phytoestrogens can bind to estrogen receptors (ERs) to exert context-dependent estrogenic and/or anti-estrogenic effects. As such, there are potential health benefits and risks associated with phytoestrogen exposure. To investigate the effects of Nar in breast cancer, based on its activity as a phytoestrogen, we treated MCF-7 ER-positive (ER+) breast cancer cells with Nar (10 µM) and examined transcriptomic changes in MCF-7 cells induced by Nar treatment. Pathway analysis included in our dataset shows upregulation of genes associated with estrogen signaling and epithelial-to-mesenchymal transition in breast cancer cells treated with naringenin.
